COWLEY, MICHAEL A.,TOLLEFSON, GARY,MKINNEY, ANTHONY A.
申请号：
ARP170101009
公开号：
AR108614A2
申请日:
2017.04.19
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
Claim 1: a method for reducing Food cravings,Characterized in that it comprises: identify a subject with food cravings； and administering a First compound and a Second Compound to the subject in an amount that is effective for reducing anGorse food； where the first Compound is selected from an opioid antagonist and an anticonvulsant； and where the second Compound is an Enhancer activity to - MSH.Claim 3: the method of any one of claims 1 to 2, wherein the opioid antagonist alvimopan is selected, norbinaltorfimina, nalmefena, naloxoneNaltrexone, methylnaltrexone, nalorphine, and pharmaceutically acceptable salts, prodrugs or Metabolites of the same.Method 4: the claim of any of claims 1 to 3, wherein the opioid antagonist is selected between Naltrexone and 6 - B naltrexol.The Method of claim 6: any of claims 1 to 5Wherein the Enhancer activity of - MSH is a selective serotonin reuptake inhibitor (SSRI) and / or an agonist specific 5-ht receptor.Claim 7: Method of claim 6, wherein the IRSS is selected between fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, Sibutramine,Duloxetine, Venlafaxine, and pharmaceutically acceptable salts, prodrugs or Metabolites of the same.The Method of claim 8: any of claims 1 to 5, wherein the Enhancer activity of - MSH is bupropion.The Method of claim 9: any of claims 1 to 8, wherein the anticonvulsant Topiramate, zonisamide is selected, Nembutal, lorazepam, clonazepam,Clorazepate, tiagabine, Fosphenytoin, phenytoin, gabapentin, carbamazepine, Valproate, Felbamate, Lamotrigine, levetiracetam, oxcarbazepine, methsuximide, and etosuxmida,Salts and pharmaceutically acceptable prodrugs or Metabolites of the same.Package: a claim 27 characterized in that it comprises: a First compound and a Second Compound In Unit dosage form； and written instructions advising the Reader to manage the dOsis Unitary Vessel expected to alleviate Food cravings, where the first Compound is selected from an opioid antagonist and an antic
